Community
TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
अप्रै. २८, २०२६
2 min read
39

EssilorLuxottica's CEO, Francesco Milleri, expressed confidence that the company's shares will recover from a significant drop. The stock has fallen over 40% due to U.S. tariffs, a weaker dollar, geopolitical conflicts, and competition in the smart eyeglasses market.
The Franco-Italian eyewear group's stock has been under pressure since hitting a record high in November. Finance chief Stefano Grassi confirmed that U.S. tariffs alone had a 300 million euro impact last year. Milleri also attributed the downturn to the company's strategic push into the medtech sector, describing it as a necessary transformation for long-term growth beyond traditional eyewear.
Despite investor concerns about competition in smart eyewear, Milleri downplayed the threat, stating no truly competitive products have yet emerged on the market. He believes the medtech pivot will eventually yield positive results. The company continues its partnership with Meta Platforms on Ray-Ban smart glasses, but Milleri cautioned that regaining the stock's previous valuation will take time.
EssilorLuxottica is navigating external economic pressures alongside a significant internal transformation. The leadership's long-term outlook remains positive, banking on its strategic shift to medtech and innovation in smart eyewear to drive a future share price recovery.
Q: Why did EssilorLuxottica's stock price fall over 40%?
A: The decline is attributed to a combination of factors, including the financial impact of U.S. tariffs, a weaker dollar, and investor concerns over competition in the smart glasses market and a strategic shift into medtech.
Q: What is EssilorLuxottica's strategy for recovery?
A: The company's strategy is focused on completing its transformation into a medtech player and maintaining its market-leading position in smart eyewear through its collaboration with Meta Platforms.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles